Clinical Trial Detail

NCT ID NCT02425683
Title Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements no
Sponsors US Oncology Research
Indications

colorectal cancer

Therapies

Regorafenib

Age Groups: adult

No variant requirements are available.